SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) 鈥 Shanghai Junshi Biosciences Co., Ltd (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the 鈥淣MPA鈥? has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, 鈥淰V116鈥?, an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (鈥淐OVID-19鈥?.